new eu derm/rheum survey indic humira eros could much wors
remain neutral rate share lower ex-u humira estim
follow recent survey feedback eu rheumatologist dermatologist
suggest downsid potenti brand humira eros hand biosimilar
competit manag downwardli revis humira ex-u eros estim
twice recent month y-i last novemb y-i last month
suspect seen last revis specif eu derm rheum
project biosimilar captur adalimumab use think
contrast manag eros commentari given feedback
model ex-u humira eros still fear could wors given
setup continu urg caution name despit healthi dividend yield
time eu doc survey midst eu humira biosimilar competit
highlight herein new eu rheumatologist dermatologist survey
field partner spherix global insight indic physician
expect biosimilar adalimumab convers ra pso
coupl indic doc gener see clinic differenti
brand humira biosimilar hard press see payer
author dont push even faster convers altern
lower ex-u humira estim given feedback think prudent
lower ex-u humira estim model ex-
us humira sale respect
sensit analysi indic ep impact could substanti
acknowledg retain signific ep leverag even declin asset
yield new lower ep estim notabl howev ex-u humira
eros even could mean ep ceteri paribu
backfil catalyst year import catalyst includ
potenti approv risankizumab psoriasi upadacitinib ra alreadi
model success across board risankizumab revenu upadacitinib
revenu see price stock alreadi
juici dividend acknowledg abbv healthi
dividend yield provid bit floor yield unheard
fact note gsk sport yield mani month day remain
moreov abbv vs large-cap peer median
appear compel think environ downward estim revis
argument much thinner given prefer watch play sidelin
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
rheumatologist
remain neutral rate share lower ex-u humira estim
follow recent survey feedback eu rheumatologist dermatologist suggest
downsid potenti brand humira eros hand biosimilar competit
manag downwardli revis humira ex-u eros estim twice recent month
y-i last novemb y-i last month suspect seen
last revis specif eu derm rheum project biosimilar captur
adalimumab use mid-year think contrast sharpli manag
full year eros commentari given feedback model ex-u humira
eros still fear could wors given setup continu urg caution
partner spherix global insight field two larg physician survey rheumatologist
dermatologist countri detail
ra survey field octob particip survey
rheumatologist must practic year least ra patient
manag spend least time clinic practic see patient rheum
particip studi evenly-divid germani franc itali spain
uk averag survey doc ra patient manag repres roughli
patient eu moderate/sever ra popul
pso survey field decemb januari particip
survey dermatologist must practic year least pso
patient manag spend least time clinic practic see patient
practic focus cosmet dermatolog survey includ
respons dermatologist evenli split germani franc itali spain
uk
acknowledg somewhat limit util octob rheumatologist feedback given
survey field concurr humira eu loe octob concurr
launch four biosimilar still find project biosimilar share data use given tnf
captur two-third eu biolog use ra versu biolog use plu overal lower
biolog penetr rate among eu derm movement toward amoa would place
weight rheumatologist feedback derm feedback discern trend eu brand humira
use said find recent dermatologist feedback valid earli
page
increas use
jak
eu seen new market entrant includ xeljanz olumi kevzara
past sever quarter overal market share remain fairli stabl survey humira
captur share roughli consist survey share see
enbrel/etanercept likewis maintain share though
product includ brand biosimilar expect see slight eros come six
month rheumatologist increas use olumi xeljanz kevzara
current futur biologic/jak use ra
enbrel rituxan
humira
question month ra patient treat biolog anticip brand alloc
variat adopt pattern biosimilar remicad infliximab enbrel etanercept
rituxan rituximab exist across countri strikingli brand product repres one-
fifth share infliximab etanercept uk rituximab appear well way similar
trend three-quart share captur biosimilar brand remicad share lower
biosimilar infliximab share germani itali addit uk trend franc spain
similar though brand remicad retain slight major use
brand enbrel rituxan still garner major share countri asid uk
though lost ground sinc survey work instanc germani brand
enbrel captur share though fallen itali spain
also seen brand eros brand enbrel fall share
respect trend similar rituxan
interest us howev initi feedback biosimilar adalimumab share
earli survey work indic quickest eros occur germani biosimilar
share spain biosimilar share second half octob clearli caveat
initi read adalimumab biosimilar adopt nonetheless dovetail well
manag commentari report brand humira revenu
page
share biosimilar refer product ra
question consid patient treat follow agent percent brand percent biosimilar franc germani itali
take closer look biosimilar adalimumab adopt chart show rheumatologist
report brand biosimilar share given prescrib physician alway
necessarili know biosimilar brand prescrib rheum survey field
biosimilar launch put much stock use trend biosimilar
brand point would take report biosimilar share repres
physician familiar brand compani german physician report use cyltezo
though bi isnt launch eu point german doc like familiar
brand sinc bi german compani front amgn amgevita appear
best start though continu watch trend
question consid patient treat follow agent percent brand percent biosimilar
page
use rheumatologist feedback view six-month project adalimumab use
respond expect brand humira would captur adalimumab share
versu biosimilar amgen amgevita samsung bioepiss imraldi
appear pois benefit trend expect captur
recal indic eu repres total intern humira
busi share reduct ex-u busi thu line well
compani guidanc call oper reduct ex-u humira revenu howev
doesnt take account price headwind reduct brand share
even volum growth cite manag provid partial off-set given
wonder guidanc conserv enough implic thereaft
wors model
question follow tnf brand pleas provid anticip month project use broken brand vs biosimilar use
page
accept
biosimilar still
somewhat
divis issu
backdrop on-going launch multipl humira biosimilar appear us eu
physician gener becom accept biosimilar use grant remain
somewhat divis issu nearli four year eu launch first anti-tnf
biosimilar remsima/inflectra one-quart respond say comfort
approv biosimilar interchang refer brand howev higher percentag
agre statement remain say neutral cours
countri decent amount variat uk doc indic highest
averag comfort biosimilar correspond uk higher biosimilar share
remicad enbrel doc itali spain cautiou
said consist rest survey feedback present overwhelm
sentiment biosimilar use increas treatment ra countri indic
fulli respond
question pleas rate level agreement follow statement strongli disagre strongli agre
page
say
experi also
treatment trend
contrast dermatologist feedback suggest less comfort accept biosimilar use
show statement agreement dermatologist evenli split
rheum ask confid biosimilar clinic equival refer
brand one-third disagre one-third agre one-third neutral statement
addit close derm express disagr idea would
hesit use biosimilar place brand product versu agre
exactli surpris derm gener express hesit biosimilar
rheumatologist given use brand biosimilar option avail
time infliximab etanercept much less aggress psoriasi patient
inde overal biolog use psoriasi remain rel lower eu compar
us even eu biolog use ra illustr exhibit show biolog use
pso still grow doc say substanti increas past year
half say slightli increas still much growth driven introduct new
agent altern moa like
dermatologist less accept biosimilar use rheum
question pleas rate level agreement follow statement use scale strongli disagre
page
question patient manag psoriasi percent fall follow categori past year use biolog chang
treatment pso pleas alloc point reason use biolog agent increas past year report increas
evid dermatologist feedback current futur brand share among
biologic-tr pso patient adalimumab stelara current lead share
respect expect declin next six month favor tremfya
taltz kyntheum siliq shown exhibit
current futur brand share among biolog treat patient pso
question consid pso patient biologics/jak pleas alloc percent patient follow brand total equal
month pso patient treat biologics/jak anticip brand alloc refer current brand usag provid consid
pso patient current treat biolog percent fall follow categori
page
biosimilar use
current project brand biosimilar adalimumab trend dermatologist feedback
gener line rheumatologist feedback derm survey field late-
match biosimilar share report rheum late octob survey
derm project biosimilar adalimumab captur humira share come six
month versu rheumatologist project given differ attitud toward
biosimilar among derm rheum highlight less-domin role tnf
biolog eu pso treatment gener think expect dermatologist
project lower biosimilar share fact given differ rheum/derm
market take dermatologist feedback support rheumatologist feedback
question indic xx biolog psoriasi patient treat adalimumab pleas alloc percent adalimumab use across follow brand indic
next six month xx biolog treat patient prescrib adalimumab pleas alloc percent adalimumab use
page
bioepi sandoz
rep hit
show biosimilar repres contact rate report dermatologist amgn
amgevita rep far highest contact rate contact close survey doc
samsung bioepiss imraldi sandoz hyrimoz rep far behind contact roughli
one-quart respond within month post-launch overal derm contact rate
pretti low infliximab etanercept biosimilar well respect launch see
biosimilar adalimumab appear way aggress market effort
may also lead higher biosimilar adopt doc current project
question contact compani repres follow biosimilar product
page
guidanc
bit move
evolv project mid-teen eu humira eros within year biosimilar
competit eros within first year launch see consist downward
revis part base premis humira ex-u eros curv would look similar
remicad enbrel initi eros guidanc also factor ex-u humira
volum growth high-singl digits/low-doubl digit therefor expect act
partial off-set price declin share loss biosimilar entrant see manag
commentari bold exhibit
biosimilar
competit
retrospect evidenc manag recent humira eros guidanc revis
use remicad enbrel proxi humira eros post-lo underestim impact
four biosimilar enter market simultan mid-octob amgen amgevita
hulio samsung bioepiss imraldi sandoz hyrimoz comparison third biosimilar
remicad launch late last year enbrel biosimilar competit remain limit
benepali erelzi roughli three year initi biosimilar entri
page
dateex-u humira eros guidanc compar anticip moder eros direct humira biosimilar competit begin humira sale peak start declin move two year year character eros intern humira busi said impact opportun cost would greater without biosimilar competit humira would continu grow intern market beyond period time think two compon part compon take price market reduc market growth compon biosimilar may take new patient take market growth way say impact brand peak point declin period expect brand intern peak start modest eros curv see biosimilar enter marketplac outsid us fourth quarter mmove forward model go forward way essenti would see peak eros rememb unlik drug grow volum fact grow volum outsid unt state rate high singl digit low double-digit volum increas look brand biosimilar enter marketplac grow volum therefor would greater impact revenu erod period time pointshigherthanwhatwewould plan assumpt back year two ago look atthenew clarif describ level eros would expect moder impact correct describ two-year period expect intern humira approxim oper basi reflect impact biosimilar competit outsid usth number describ roughli point assum eros yet occur came origin guidanc back base saw marketplac primarili time remicad follow enbrel exhibit
chart attempt compar impact biosimilar avail ex-u eu
revenu humira versu remicad enbrel rituxan/mabthera quarter biosimilar
launch quarter subsequ quarter note biosimilar market
week ex-u humira thu greater proportion declin revenu compar
averag quarterli revenu four quarter preced biosimilar launch enbrel
remicad declin low- mid-teen quarter biosimilar
ex-u eu eros curv biosimilar entri remicad enbrel mabthera humira
note ex-u humira figur quarter post-lo repres pjc estim
exhibit graph data eros curv biolog clearli didnt
follow straight-lin trajectori downward see chart quarterli revenu brand biolog
saw quarter-to-quart variabl dynam drive sever humira
biosimilar eros give us paus particularli move thereaft
given brand biolog compar differ level base sale pre-biosimilar
entri compar estim proportion estim ex-u humira revenu
fourth full quarter biosimilar entri compar quarter biosimilar
introduc quarter quarter repres declin comparison
compar quarter quarter rituxan declin enbrel declin
remicad declin note may somewhat confound roch
detail report break eu rituxan revenu oppos lump togeth
page
overal ex-u sale still given survey feedback outlin herein experi past
eu brand eros wouldnt surpris new estim prove optimist
page
lower
estim
still wonder
could substanti
given continu downward guidanc revis survey feedback highlight
think prudent lower ex-u humira revenu estim well year
previou ex-u humira estim y/i consist
compani recent guidanc lower estim y/i
bring ww humira revenu estim consensu
year remain consensu
fulli acknowledg retain signific ep leverag even declin asset
said lower ww humira revenu estim lower ep
estim factset consensu
howev ex-u eros faster current estim ep impact sever
assum y/i ex-u humira eros consist margin would bring ep
estim y/i ex-u humira eros would bring ep estim
current consensu
continu deriv price target share appli multipl
ep estim discount though ep estim come
slightli off-set laps partial discount period price target remain
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
row revenu
elotuzumab revenu
total ww elotuzumab revenu
row profit share
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
